Skip to main content Accessibility help
×
Home
  • Print publication year: 2008
  • Online publication date: December 2009

61 - Septic Shock

from Part III - Special Populations
    • By Clement Yeh, Clinical Instructor of Emergency Medicine, University of California, San Francisco School of Medicine, San Francisco General Hospital, San Francisco, CA, Robert Rodriguez, Professor of Medicine, University of California, San Francisco School of Medicine, San Francisco General Hospital, San Francisco, CA
  • Edited by Rachel L. Chin, University of California, San Francisco
  • Publisher: Cambridge University Press
  • DOI: https://doi.org/10.1017/CBO9780511547454.062
  • pp 403-408

Summary

INTRODUCTION

The term sepsis describes a spectrum of pathophysiologic responses to infection. In the setting of advanced antibiotic therapies, sophisticated respiratory and cardiovascular support, and improved diagnosis, sepsis-associated mortality has declined in recent years, though it remains greater than 50% in some groups. Early recognition and aggressive management are critical to reducing morbidity and mortality.

EPIDEMIOLOGY

The causative organisms implicated in sepsis have changed over time, and many cases have nondiagnostic or negative cultures. The identified sites of primary infection are predominantly lung (47%), followed by unknown/other (28%), peritoneum (15%), and urinary tract (10%). Prior to 1987, gram-negative organisms were the predominant organisms identified. In the past 20 years, however, sepsis caused by gram-positive organisms has increased markedly, and gram-positives are now the predominant etiologic agents. Additionally, over the same time period, the incidence of fungal sepsis has increased by over 200%. These changes likely reflect the increased numbers of immunocompromised patients and debilitated surgical patients, and the increased use of indwelling catheters and devices.

CLINICAL FEATURES

The American College of Chest Physicians and the Society of Critical Care Medicine have developed standardized diagnostic criteria for sepsis, severe sepsis, and septic shock to describe the continuum of evolving physiologic derangement (Table 61.1). Categorization of patients in this system provides vital prognostic information and guides critical disposition and treatment decisions.

Related content

Powered by UNSILO
REFERENCES
Angus, D C, Laterre, P, Helterbrand, J, et al. The effect of drotrecogin alfa (activated) on long term survival after severe sepsis. Crit Care Med 2004; 32: 2199–206.
Angus, D C, Wax, R S. Epidemiology of sepsis: An update. Crit Care Med 2001; 29: S109–16.
Annane, D, Sebille, V, Charpentier, C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone of mortality in patients with septic shock. JAMA 2002; 288: 862–71.
Bernard, G R. Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis. Crit Care Med 2003; 31: S85–93.
Bochud, P Y, Bonten, M, Marchetti, O, et al. Antimicrobial therapy for patients with severe sepsis and septic shock: an evidence-based review. Crit Care Med 2004; 32: S495–512.
Centers for Disease Control and Prevention (CDC). Increase in national hospital discharge survey rates for septicemia: United States, 1979–1987. MMWR 1990; 39: 31–4.
Dellinger, R P, Carlet, J M, Masur, H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004; 32: 858–73.
Forsythe, S M, Schmidt, G A. Sodium bicarbonate for the treatment of lactic acidosis. Chest 2000; 117: 260–7.
Hotchkiss, R S, Karl, I E. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 342: 138–50.
Krisnagopalan, S. Myocardial dysfunction in the patient with sepsis. Curr Opin Crit Care 2002; 8: 376–88.
Mitchell, M M, Fink, M P, Marshall, J C, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31: 1250–6.
Rangel-Frausto, M, Pittet, D, Costigan, M, et al. The natural history of the systemic inflammatory response syndrome (SIRS): a prospective study. JAMA 1995; 273: 117–23.
Rivers, E, Nguyen, B, Havstad, S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345: 1368–77.
Santacruz, J F, Zavala, E D, Arroliga, A C. Update in ARDS management: recent randomized controlled trials that changed our practice. Cleve Clin J Med 2006; 217–36.
The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000; 342: 1301–8.
Berghe, G, Wilmer, A, Milants, I, et al. Intensive insulin therapy in mixed medical/surgical intensive care units. Diabetes 2006; 55: 3151–9.
Ware, L B, Matthay, M A. The acute respiratory distress syndrome. N Engl J Med 2000; 342: 1334–49.
ADDITIONAL READINGS
Bernard, G R, Wheeler, A P, Russell, J A, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. N Engl J Med 1997; 336: 912–8.
Dellinger, R P. Cardiovascular management of septic shock. Crit Care Med 2003; 31: 946–55.
Vincent, J L, Fink, M P, Marini, J J, et al. Intensive care and emergency medicine: progress over the last 25 years. Chest 2006; 129: 1061–7.